Parkman Healthcare Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Parkman Healthcare Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.92M	Buy	235,000 +172,970	+279%	+$3.9M	0.51%	56
2025 Q4	$1.43M	Sell	62,030 -6,606	-10%	-$217K	0.14%	87
2025 Q3	$2.06M	Sell	68,636 -79,344	-54%	-$2.38M	0.22%	81
2025 Q2	$5.38M	Sell	147,980 -156,264	-51%	-$5.63M	0.62%	59
2025 Q1	$11M	Buy	304,244 +204,085	+204%	+$8.49M	1.31%	28
2024 Q4	$4.21M	Sell	100,159 -9,309	-9%	-$462K	0.56%	49
2024 Q3	$6.08M	Buy	109,468 +9,468	+9%	+$482K	0.78%	44
2024 Q2	$4.11M	Buy	+100,000	New	+$4.27M	0.55%	61

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Parkman Healthcare Partners's RARE Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Ultragenyx Pharmaceutical (RARE) stake by 279% in Q1 2026, buying an estimated $3.9M and bringing the position to 235,000 shares worth $4.92M. The position accounts for 0.51% of the portfolio, ranked #56.

Parkman Healthcare Partners first reported a position in RARE in Q2 2024 and has held it in 8 quarters since. The position peaked at $11M in Q1 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Parkman Healthcare Partners held 235,000 shares of Ultragenyx Pharmaceutical worth $4.92M as of Q1 2026.
Parkman Healthcare Partners bought 172,970 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.9M.
Ultragenyx Pharmaceutical made up 0.51% of Parkman Healthcare Partners's portfolio in Q1 2026, its #56 holding.
Parkman Healthcare Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and has held it in 8 quarters since.
Parkman Healthcare Partners's Ultragenyx Pharmaceutical position peaked at $11M in Q1 2025.
296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.